Citizens Initiates Coverage On Opus Genetics with Market Outperform Rating, Announces Price Target of $12

Benzinga Newsdesk www.benzinga.com Neutral 54.5%

Neg 0% Neu 54.5% Pos 0%

Citizens analyst Jonathan Wolleben initiates coverage on Opus Genetics (NASDAQ:IRD) with a Market Outperform rating and announces Price Target of $12.